Q3 2017 Earnings Forecast for Agios Pharmaceuticals, Inc. Issued By Oppenheimer Holdings (AGIO)
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at Oppenheimer Holdings decreased their Q3 2017 earnings estimates for Agios Pharmaceuticals in a research note issued to investors on Tuesday. Oppenheimer Holdings analyst L. Cann now expects that the biopharmaceutical company will post earnings per share of ($1.99) for the quarter, down from their prior estimate of ($1.96). Oppenheimer Holdings has a “Buy” rating and a $75.00 price target on the stock. Oppenheimer Holdings also issued estimates for Agios Pharmaceuticals’ Q4 2017 earnings at ($2.04) EPS, Q1 2018 earnings at ($2.31) EPS, Q2 2018 earnings at ($2.31) EPS, Q3 2018 earnings at ($2.45) EPS, Q4 2018 earnings at ($0.21) EPS, FY2018 earnings at ($7.28) EPS and FY2019 earnings at ($1.43) EPS.
A number of other equities analysts have also recently commented on the company. Zacks Investment Research raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, April 28th. Janney Montgomery Scott cut Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 26th. Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, May 4th. Cann reissued a “buy” rating and set a $75.00 target price on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Finally, ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $68.67.
ILLEGAL ACTIVITY WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/q3-2017-earnings-forecast-for-agios-pharmaceuticals-inc-issued-by-oppenheimer-holdings-agio/1467462.html.
Agios Pharmaceuticals (AGIO) opened at 60.56 on Thursday. The stock’s market cap is $2.92 billion. Agios Pharmaceuticals has a one year low of $35.84 and a one year high of $67.74. The stock has a 50 day moving average price of $56.81 and a 200-day moving average price of $51.69.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by $0.21. The firm had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 75.48% and a negative net margin of 502.12%. The business’s revenue was up 62.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.47) EPS.
In other Agios Pharmaceuticals news, insider Scott Biller sold 4,292 shares of the firm’s stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $55.00, for a total transaction of $236,060.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the firm’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $47.10, for a total value of $95,895.60. Following the sale, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,120 shares of company stock valued at $4,557,207. Insiders own 10.55% of the company’s stock.
A number of large investors have recently bought and sold shares of AGIO. Swiss National Bank boosted its stake in Agios Pharmaceuticals by 3.4% in the first quarter. Swiss National Bank now owns 55,360 shares of the biopharmaceutical company’s stock valued at $3,233,000 after buying an additional 1,800 shares during the period. Spark Investment Management LLC boosted its stake in Agios Pharmaceuticals by 139.9% in the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock valued at $4,357,000 after buying an additional 49,400 shares during the period. Geode Capital Management LLC boosted its stake in Agios Pharmaceuticals by 8.3% in the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock valued at $15,410,000 after buying an additional 20,336 shares during the period. Clear Harbor Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the first quarter valued at about $270,000. Finally, Ameriprise Financial Inc. boosted its stake in Agios Pharmaceuticals by 8.5% in the first quarter. Ameriprise Financial Inc. now owns 41,029 shares of the biopharmaceutical company’s stock valued at $2,397,000 after buying an additional 3,215 shares during the period. 84.53% of the stock is owned by institutional investors.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.